Skip to content
etf.net

Launched

iShares Health Innovation Active ETF

BMEDNYSE ArcaiSharesB

$36.17−0.33 (−0.90%)

As of Nov 2, 2026, 3:33 PM ET

B61/ 100

Rank 7 of 35 in US Active Sector

B61/100Rank 7 of 35inUS Active Sector
Intraday session: down, 74 prints from 36.50 to 36.17. Range 36.07 to 36.52. Use the arrow keys to read each point.36.1036.3036.4010 AM12 PM2 PM4 PM
Expense ratio
0.55%*
Fund size
$15M
1Y total return
+28.3%
Yield · Last 12 months
0.22%
Holdings
61
Avg volume · 30D
2.15K sh
52W range
low $27.25high $36.98
Launched

*After a fee waiver that ends Jun 30, 2027. Without it: 0.77%.

The ETF.net BMED Grade

B

Score 61 out of 100

Category
US Active Sector⁠
Rank
7 of 35
Six-pillar profile for BMED. Scores out of 100: Cost 72, Risk 61, Mission 77, Tradability 31, Holdings 74, Durability 60. Strongest: Mission (77). Weakest: Tradability (31). No single pillar leads.

Score 61 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    A72 out of 100
    Rank 10 of 35

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    A77 out of 100
    Rank 5 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B61 out of 100
    Rank 12 of 35

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D31 out of 100
    Rank 29 of 35

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    A74 out of 100
    Rank 6 of 35

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    B60 out of 100
    Rank 14 of 35

Our read on BMED

ETF.net Research

In short

BMost health ETFs are a shelf of mega-cap pharma. BMED's stock pickers hunt the other end: roughly 60 innovative and emerging health names tilted to mid and small caps worldwide, 0.55% net of a waiver through June 30, 2027.

Stated mandate

The Fund seeks to maximize total return through active investment in innovative and emerging healthcare companies.

Why people hold it

  • Mandate is specific: at least 80% of net assets in health sciences stocks, with the focus on mid- and small-cap innovators anywhere in the world, emerging markets included.sec.gov
  • 0.55% net of a waiver through June 30, 2027 (0.77% gross), below the median fee among the 35 active sector funds in its group.
  • Reach goes past drugmakers: devices, diagnostics, REITs that own hospitals, even animal and plant health sit inside the prospectus definition.sec.gov
  • About 60 names means each pick carries weight, and the portfolio matches the innovation mandate it advertises, one of the stronger builds in its active sector peer group.

Worth knowing

  • Small fund, light trading. Spreads can widen and the market price can drift from net asset value, which bites hardest on bigger orders.sec.gov
  • Mid caps, small caps and emerging-market names in a book of about 60 stocks move harder in both directions than mega-cap pharma.sec.gov
  • That 0.55% leans on a waiver running to June 30, 2027; gross is 0.77%. Active healthcare peer TMED charges 0.44% with no waiver attached.

BMED Performance

Launched Sep 29, 2020

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.
BMED$12,835
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. BMED $12,835. SPY $11,199. Use the arrow keys to read each point.$10,000$11,000$12,000$13,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BMED. Periods over one year show the average yearly return.
PeriodBMED
Year to date+20.7%
1 month+5.6%
3 months+17.8%
1 year+28.3%
3 yearsper year+20.9%
5 yearsper year+4.2%
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for BMED
YearReturn barBMED
2026 YTD+20.7%

BMED in the news

BMED Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.22%Last 12 months
Payout per share
$0.08Last 12 months
Last payment
$0.08 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution history

2023–2026

One bar per payment. 2 payments from 2023 to 2026 YTD. Dec 20, 2023 $0.0072; Jun 15, 2026 $0.08. Use the arrow keys to read each point.2023202420252026YTD
Ex-datePay dateAmount per share
Jun 15, 2026Jun 18, 2026$0.08
Dec 20, 2023Dec 27, 2023$0.0072

$10,000 in BMED 5 years ago paid $29.44 in dividends.

BMED Risk

Risk pillarB61 out of 100Rank 12 of 35 in US Active Sector
How much the fund’s monthly returns vary, scaled to a year.
15.3%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
1.03
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−32.1%
Trough Sep 2022
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.74
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

BMED Cost

Compare BMED and TRUF

Overpaying vs TRUF, tied cheapest in US Active Sector

$8,798

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BMED 0.55%

    $10,904

  • TRUF 0.10% Tied cheapest

    $2,106

$10,000
30 years

Cost over time

  • BMED 0.55%
  • TRUF 0.10%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2.5K$5K$7.5K$10K$12.5K051015202530BMED $10,904TRUF $2,106

Year by year

YearBMEDTRUFOverpaying
10$988$183$805
20$3,790$717$3,073
30$10,904$2,106$8,798
How the 0.55% is worked out

Full fee 0.77%− waiver 0.22%= you pay 0.55%

The waiver ends Jun 30, 2027. After that the fee is 0.77% unless iShares renews it. Source: prospectus, Nov 2025.

Other funds in US Active Sector

See others